O
JBIO

OrbiMed’s Jade Biosciences JBIO Stock Holding History

OrbiMed’s Portfolio JBIO Stock Details JBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-185,011
Closed -$2.6M – 133
2026
Q1 		$2.6M Sell
185,011
-346,152
-65% -$5.01M 0.05% 105
2025
Q4 		$8.2M Hold
531,163
– – 0.17% 85
2025
Q3 		$4.58M Hold
531,163
– – 0.11% 87
2025
Q2 		$5.31M Buy
+531,163
New +$18.1M 0.13% 76
2024
Q2 		– Sell
-16,154
Closed -$16.7M – 117
2024
Q1 		$16.7M Sell
16,154
-5,473
-25% -$4.18M 0.31% 71
2023
Q4 		$17.1M Hold
21,627
– – 0.34% 65
2023
Q3 		$10.3M Hold
21,627
– – 0.22% 83
2023
Q2 		$13M Hold
21,627
– – 0.24% 80
2023
Q1 		$15.3M Sell
21,627
-74
-0.3% -$61.4K 0.3% 75
2022
Q4 		$22.3M Sell
21,701
-1,013
-4% -$735K 0.43% 64
2022
Q3 		$13.2M Buy
22,714
+9,040
+66% +$6.03M 0.24% 78
2022
Q2 		$7.48M Sell
13,674
-896
-6% -$428K 0.14% 101
2022
Q1 		$9.35M Sell
14,570
-736
-5% -$286K 0.15% 102
2021
Q4 		$6.32M Hold
15,306
– – 0.08% 128
2021
Q3 		$11.2M Hold
15,306
– – 0.12% 120
2021
Q2 		$12.2M Buy
+15,306
New +$12.2M 0.12% 118

Other funds holding JBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

OrbiMed's JBIO Position: Q2 2026 in Review

OrbiMed sold out of Jade Biosciences (JBIO) in Q2 2026, closing a stake of 185,011 shares — an estimated $2.6M sold.

OrbiMed first reported a position in JBIO in Q2 2021 and held it in 16 quarters. The position peaked at $22.3M in Q4 2022. 154 funds tracked by Wall St. Rank hold JBIO as of Q2 2026.

  • OrbiMed reported no remaining Jade Biosciences position as of Q2 2026 after selling out during the quarter.
  • OrbiMed sold 185,011 Jade Biosciences shares in Q2 2026, an estimated $2.6M.
  • OrbiMed first reported a position in Jade Biosciences in Q2 2021 and held it in 16 quarters.
  • OrbiMed's Jade Biosciences position peaked at $22.3M in Q4 2022.
  • 154 funds tracked by Wall St. Rank held Jade Biosciences as of Q2 2026.

Based on OrbiMed's 13F filing for Q2 2026, filed 14 Aug 2026.